Syneos Health Inc.’s stock SYNH soared 9% in premarket trade Wednesday, after the biopharma services company said it has agreed to be acquired by a private investment consortium for about $7.1 billion in cash. Under the terms of the deal, the consortium of Elliott Investment Management, Patient Square Capital and Veritas Capital will pay $43 per Syneos Health stock, equal to a 24% premium over the stock’s closing price on Feb. 13, the last trading day prior to media reports of a possible deal.
Under the terms of the deal, the consortium of Elliott Investment Management, Patient Square Capital and Veritas Capital will pay $43 per Syneos Health stock, equal to a 24% premium over the stock’s closing price on Feb. 13, the last trading day prior to media reports of a possible deal.
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Investment consortium nears deal for Syneos Health -sourcesA consortium comprising Elliott Investment Management, Patient Square Capital and Veritas Capital is nearing a deal to acquire Syneos Health Inc , a provider of clinical research to drug developers with a market value of $4 billion, people familiar with the matter said.
Read more »
Investment consortium nears $7 bln-plus deal for Syneos Health -sourcesA consortium comprising Elliott Investment Management, Patient Square Capital and Veritas Capital is nearing a deal to acquire Syneos Health Inc , a provider of clinical research to drug developers, for more than $7 billion, including debt, people familiar with the matter said.
Read more »